Prelude Therapeutics Inc Segments Disclosure
9. Segments
The Company currently operates as one operating business segment focused on developing innovative medicines in areas of high unmet need for cancer patients. The Company's determination that it operates as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker ("CODM") for purposes of evaluating performance, allocating resources, and planning and forecasting for future periods.
The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the segment based on net loss, which is reported on the statement of operations and comprehensive loss as net loss. The measure of segment assets is reported on the balance sheet as total assets.
To date, the Company has not recognized any revenue from product sales, and the Company does not expect to generate any revenue from product sales in the foreseeable future. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and to make decisions about the allocation of resources, along with cash forecast models.
The following tables summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025, and 2024. Included in Other are programs such as PRT2527, PRT1419, and PRT3645.
|
|
Year ended December 31, |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Revenue from license agreement |
|
$ |
12,140 |
|
|
$ |
7,000 |
|
|
|
|
|
|
|
|
||
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
|
|
|
|
||
PRT3789 |
|
$ |
13,461 |
|
|
$ |
20,173 |
|
PRT7732 |
|
|
9,145 |
|
|
|
9,195 |
|
Discovery programs, including JAK2V617F, KAT6A and mCALR |
|
|
12,129 |
|
|
|
13,856 |
|
Other |
|
|
3,475 |
|
|
|
12,940 |
|
General costs, including personnel related |
|
|
56,090 |
|
|
|
61,831 |
|
Total research and development |
|
|
94,300 |
|
|
|
117,995 |
|
General and administrative |
|
|
22,406 |
|
|
|
28,719 |
|
Total operating expenses |
|
$ |
116,706 |
|
|
$ |
146,714 |
|
Loss from operations |
|
|
(104,566 |
) |
|
|
(139,714 |
) |
Other income, net |
|
|
5,068 |
|
|
|
12,541 |
|
Net loss |
|
$ |
(99,498 |
) |
|
$ |
(127,173 |
) |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 10, 2026 | Showing above |
| 2024 | Mar 10, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.